Sutura, Inc.
OTC Bulletin Board : SUTU

Sutura, Inc.

October 05, 2005 08:38 ET

Interview with Sutura CEO Anthony Nobles Available at Wall Street Reporter Magazine

FOUNTAIN VALLEY, CALIFORNIA--(CCNMatthews - Oct. 5, 2005) - Sutura®, Inc. ("Sutura")(OTCBB:SUTU), a California-based medical device company, announced today that its President and CEO, Anthony Nobles, is featured in an online interview at Wall Street Reporter Magazine. In the interview, Nobles provides an overview of the Company and discusses the latest developments relating to its line of proprietary SuperStitch medical devices. The interview is available at http://www.wallstreetreporter.com/linked/SUTURAINC.html

Sutura, Inc. recently announced that the United States Patent and Trademark Office has granted the Company allowance of another patent for the its vessel closure technology. This patent will further strengthen Sutura's intellectual property with respect to the Company's core SuperStitch technology.

The Company also announced September 20, 2005 the addition of three new veteran sales representatives to its expanding national SuperStitch sales force. These experienced vascular product sales representatives bring a wealth of knowledge and contacts within the southeastern region of the country and have a combined 17 years experience selling competitive devices in that area.

On September 9, 2005 Sutura, Inc. reported it had closed a $7 million financing with Minneapolis-based Whitebox Advisors, LLC. Proceeds from the round of financing will be used to move the Company into its next stage of development and support the expansion of the worldwide marketing and sales plan for the Sutura's SuperStitch vascular suturing device.

About Sutura, Inc.

Sutura®, Inc. (www.suturaus.com) is a medical device company that has developed a line of innovative, minimally invasive, vascular suturing devices to suture the puncture created in arteries during open surgery and catheter-based procedures. The Company's line of SuperStitch medical devices provide sutured closure of the arteriotomy site utilizing the existing catheter sheath introducer or cannula during fluoroscopically guided procedures and directly through the open arteriotomy during open surgical procedures.
Within the United States the F8 & F6 SuperStitch devices are available for use in performing vascular stitching in general surgery, including endoscopic procedures. It is not intended for blind closure of an arteriotomy site. The SuperStitch F8 & F6 is approved in the European Union and CE marked with the indication for use as follows: The SuperStitch is indicated for use in performing vascular stitching in general surgery, including endoscopic procedures. In the EU there is no requirement for the use of fluoroscopic guidance. Sutura's headquarters are in Fountain Valley, California. "Sutura®" and "SuperStitch®" are registered trademarks of Sutura, Inc.

Forward-Looking Information Is Subject to Risk and Uncertainty

Certain statements in this press release may contain projections or "forward-looking" information (as defined in the Private Securities Litigation Reform Act of 1995) that involve risk and uncertainty. The words "aim", "plan", "likely", "believe", "expect", "anticipate", "intend", "estimate", "will", "should", "could", "may","appears", and other expressions that indicate future events and trends identify forward-looking statements. These statements are not guaranties of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what we express or forecast in these forward-looking statements. As a result, these statements speak only as of the date they were made and we undertake no obligation to publicly update or revise any forward-looking statements. Our actual results and future trends may differ materially from our forward-looking statements depending on a variety of factors including the acceptance of the SuperStitch® devices by medical providers and the marketplace in general and the success of the proposed marketing plan, the continued growth of the vessel closure marketplace and the company's ability to continue to expand and protect its technology patents.

Contact Information

  • Sutura, Inc.
    Barry Forward
    Corporate Communications
    (866) 676-8386
    www.suturaus.com